Tirzepatide Shows Promising Weight Loss Results in Non-Diabetic Adults
A real-world study has demonstrated the effectiveness of tirzepatide, a dual GIP/GLP-1 receptor agonist, in promoting weight loss among adults with obesity but without diabetes. Conducted over 12 weeks, the study involved 115 participants who received low-dose tirzepatide. Results showed an average weight loss of 8.2 kg and a reduction in BMI, with 46.1% of participants achieving at least 5% weight loss. The study also noted improvements in metabolic parameters such as HbA1c and LDL cholesterol. Nausea was the most common side effect, leading to a 10.4% discontinuation rate. 
